Chemotherapy or Chemotherapy Plus PD-1 Antibody in RET Fusion Positive Advanced NSCLC Patitnts: the POSEIDON Trial
NCT04322591
·
clinicaltrials.gov ↗
UNKNOWN
Status
70
Enrollment
OTHER
Sponsor class
Conditions
Non-small Cell Lung Cancer
Sponsor
Hunan Province Tumor Hospital